Trial Title:
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
NCT ID:
NCT05737212
Condition:
Recurrent High-grade Glioma
Recurrent Glioblastoma
Recurrent Anaplastic Astrocytoma
Recurrent Anaplastic Oligodendroglioma
Conditions: Official terms:
Glioblastoma
Glioma
Astrocytoma
Oligodendroglioma
Recurrence
Conditions: Keywords:
Boron neutron capture therapy
boronophenylalanine
neutron capture therapy
Study type:
Interventional
Study phase:
Phase 1/Phase 2
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Sequential Assignment
Intervention model description:
In the Phase I clinical study, the 3+3 dose escalation design is applied to evaluate the
dose limiting toxicity (DLT) and 3 study subjects are enrolled to each group (Group 1,
Group 2, Group 3). Depending on whether or not DLT occurs, 3 subjects at minimum to 18
subjects at maximum are enrolled.
However, in the event a subject assigned a subject number withdraws from the study before
starting BNCT or within 90 days from starting BNCT for reasons other than safety, up to 3
additional subjects can be enrolled for each dose group, resulting in 27 subjects at
maximum allowed for enrollment for the Phase I clinical study.
In the Phase IIa clinical study, up to 12 subjects are enrolled. However, subjects who
are included in a group that has received the radiation dose confirmed as the maximum
tolerated dose (MTD) in the Phase 1 clinical study AND satisfy all inclusion/exclusion
criteria of the Phase IIa are included in the number of subjects of Phase IIa.
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Radiation
Intervention name:
500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 9Gy-Eq
Description:
Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours.
Thereafter, patient will receive neutron irradiation simultaneously for a certain period
of time based on his Boronophenylalanine (BPA) concentration in the blood.
Arm group label:
Group 1
Intervention type:
Radiation
Intervention name:
500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 11Gy-Eq
Description:
Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours.
Thereafter, patient will receive neutron irradiation simultaneously for a certain period
of time based on his Boronophenylalanine (BPA) concentration in the blood.
Arm group label:
Group 2
Intervention type:
Radiation
Intervention name:
500mg/kg/3hr followed by neutron irradiation to reach maximum brain dose of 13Gy-Eq
Description:
Patients will be infused DMX-101 intravenously at a dose of 500mg/kg/hr over 3 hours.
Thereafter, patient will receive neutron irradiation simultaneously for a certain period
of time based on his Boronophenylalanine (BPA) concentration in the blood.
Arm group label:
Group 3
Summary:
This is a multi-centered, radiation dose escalation, open, exploratory, Phase 1/2a
clinical trial on the safety, efficacy and pharmacokinetic characteristics of BNCT in
patients with recurrent high-grade gliomas.
The Phase I clinical study is to explore the adequate radiation dose level of BNCT based
on confirmation of the maximum tolerated dose (radiation dose) of BNCT in patients with
recurrent high-grade gliomas and characterize the safety, efficacy and pharmacokinetics.
To evaluate the primary objective of tolerability, subject population with history of
exposure to a similar treatment recurrent high-grade glioma who received prior standard
radiotherapy will be recruited.
The Phase IIa is to confirm the efficacy and safety after irradiation of radiation dose
confirmed in the Phase I clinical study. To evaluate the primary objective of efficacy,
subject population with glioblastoma (The 2021 WHO Classification of Tumors of the
Central Nervous System, Glioblastoma IDH-wild type, WHO Grade 4) will be recruited.
Detailed description:
The subject receives the study drug administration and neutron irradiation in the BNCT
clinic with all procedures performed under the control by the investigator affiliated to
the study site. 500 mg/kg of the study drug is intravenously administered over 3 hours at
a constant rate and neutron irradiation starts at 1 hour after the end of the study drug
administration according to the previously established neutron irradiation plan.
All patients will be evaluated for response using magnetic resonance imaging (MRI) using
RANO and modified RANO criteria.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. An adult at the age 19 or above to under 80 at the time of written consent
2. Individual diagnosed with the following according to the WHO classification (2021)
- Astrocytoma, IDH-mutant, WHO grade 3, 4
- Oligodendroglioma, IDH-mutant, and 1p/19q-codeleted, WHO grade 3
- Glioblastoma, IDH wildtype, WHO grade 4
- Anaplastic Astrocytoma, NOS, WHO grade 3
- Anaplastic Oligoastrocytoma, NOS, WHO grade 3
- Anaplastic Oligodendroglioma, NOS, WHO grade 3
- Glioblastoma, NOS, WHO grade 4
3. Individual who received radiation therapy at the standard level (54 to 66 Gy/25 to
35 fractions) or lower
4. Individual confirmed to have disease progression* according to the RANO criteria
within 4 weeks from the screening visit (*) At least one lesion with contrast
enhancement needs to exist on the contrast enhancement MRI. For a subject who shows
no lesion with contrast enhancement, functional imaging such as 18F-FET or 18F-FDOPA
PET/CT needs to confirm the existence of at least one clear recurrent lesion.
However, in the event differentiation between recurrence and pseudoprogression is
unclear, the subject cannot participate in the screening
5. Individual who is able to lie or sit for 30 minutes to 1 hour using the fixing
device of the treatment couch
6. Individual with no metal implant such as a pacemaker
7. Individual with KPS (Karnofsky performance score) ≥ 60
8. Individual with an appropriate kidney function, lung function and bone marrow
function based on the laboratory test at the screening visit
- Hemoglobin ≥ 10.0 g/dL
- WBC (white blood cell) ≥ 3,500/μL
- Platelets ≥ 100,000/μL
- Serum creatinine ≤ 1.5xULN
- AST (aspartate aminotransferase)/ALT (alanine aminotransferase) ≤ 3xULN
9. Individual who receives sufficient explanation on the study, agrees to following the
study procedures during the study period, and voluntarily decides to participate in
the study and provides a written consent
[Phase IIa study inclusion criteria]
10. Individual histologically diagnosed with glioblastoma
11. Individual with at least one measurable observed lesion according to the modified
RANO criteria
Exclusion Criteria:
1. Individual to which a traditional therapy such as reoperation or reirradiation is
effectively applicable based on consultation with a brain tumor multidisciplinary
committee or consultation among two or more medical departments, including
neurosurgery and radiation oncology
2. Individual who received cytotoxic anticancer therapy within 4 weeks from the
screening visit (including previous interstitial anticancer therapy, local
medication, and convection-enhanced delivery)
3. Individual who received targeted anticancer therapy (e.g., bevacizumab) within 6
weeks from the screening visit
4. Individual who received radiotherapy within 6 months from the screening visit
5. Individual who received a radical surgery for high-grade glioma within 4 weeks from
the screening visit
6. Individual who received biopsy within 1 week from the screening visit
7. Individual confirmed to have a history of the following:
- Interstitial brachytherapy
- Stereotactic radiosurgery
- Reirradiation for a recurrent lesion
- Cancer immunotherapy
8. Individual with uncontrollable brain edema* even with the use of corticosteroid (*)
Uncontrollable brain edema: Uncontrolled serious headache, vomiting, dyspnea,
consciousness disturbance of NCI CTCAE (Ver. 5.0) grade 3 or above. However, for a
patient taking corticosteroid, the patient must at least be on a stable dose or dose
reduction for 7 days prior to the MRI scan at the screening visit.
9. Individual confirmed with meningeal dissemination
10. Individual diagnosed with cancer in another site* in the past at the time of the
screening visit and whose disease-free period is less than 3 years (*) Patients with
the skin basal cell carcinoma and carcinoma in situ of uterine cervix who received
radical treatment are excluded
11. Individual with hypotonic dehydration or hereditary fructose intolerance
12. Individual with current or a history of phenylketonuria
13. Individual with serious infection (e.g., sepsis, HIV) in the opinion of the
investigator
14. Individual who has dysfunction as below or, in the investigator's opinion, who is
confirmed to have clinically significant disease (e.g., unstable angina, myocardial
infarction) within 6 months from the screening visit:
- Heart disease of Class II or above according to the New York Heart Association
Functional Classification
- Chronic obstructive pulmonary disease of moderate or higher severity according
to the Chronic obstructive pulmonary disease clinical practice, or Dyspnea of
Grade II or above according to the American thoracic society dyspnea scale
- Hepatic dysfunction of Child-Pugh Classification B or C
15. Individual with current or a history of hypersensitivity to boron or any component
of the study drug
16. Individual who received or applied other investigational product or device within 4
weeks from the screening visit
17. Individual who has received prior BNCT
18. Pregnant woman, breastfeeding woman, or individual who plans pregnancy or who does
not agree to using and does not perform a medically reliable contraceptive method
during the study period
- Women of childbearing potential*: Use of 'intrauterine device', 'tubal surgery
or tubal ligation', 'chemical barrier method (spermicide) + physical barrier
method' or 'subcutaneously implanted contraceptive device + physical barrier
method' (*) Woman of any potential of pregnancy, except for those who are
before their first period, who received surgical sterilization (hysterectomy or
bilateral ovariectomy) or who reached menopause (absence of menstrual periods
for 12 months without any specific reason)
- Male: Vasectomy or use of 'male condom + use of a medically reliable
contraceptive method by the partner'
19. Individual not eligible for MRI or PET/CT scan
20. Individual the investigator otherwise considers ineligible for participating in the
study [At the treatment planning visit, the following exclusion criteria will be
checked:]
21. Individual not eligible for BNCT implementation according to the treatment plan
established with DM-BTPS
Gender:
All
Minimum age:
19 Years
Maximum age:
80 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Gachon University Gil Medical Center
Address:
City:
Incheon
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
Gi Taek Yee, M.D., Ph.D.
Email:
gtyee@gilhospital.com
Start date:
December 5, 2022
Completion date:
December 2024
Lead sponsor:
Agency:
Dawonmedax Co., Ltd.
Agency class:
Industry
Source:
Dawonmedax Co., Ltd.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05737212
